Individualized tumour therapy was the leading theme of this year's ASCO. In this context Her2Neu testing could detect a subgroup of patients suffering from advanced gastric cancer who showed substantial benefit from the addition of trastuzumab to standard chemotherapy. This first phase III trial with a biological agent is the beginning of individualized tumour therapy in gastric cancer. These data will be discussed together with other abstracts from ASCO 2009 and set into context with current therapeutic strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cunningham D, Allum WH and Stenning SP et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20
Boige V, Pignon J and Saint-Aubert B et al (2007). Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 25: 18 (Abstract No: 4510)
Schuhmacher C et al (2009). Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: randomized EORTC phase III trial. J Clin Oncol 27: 15. (Suppl; abstr 4510)
Wöll E (2008). Perioperative therapy in gastric cancer. memo 1: 71–73
Macdonald JS, Smalley S, Benedetti J, et al (2001). Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. Results of intergroup study INT-0116 (SWOG 9008). New Eng J Med 345: 725
Macdonald JS, et al. Chemoradiation of resected gastric cancer: a 10- year follow-up of the phase III trial INT0116. J Clin Oncol, 27: 15s, 2009. (Suppl; abstr 4515)
Van Cutsem E, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer. J Clin Oncol, 27: 15s, 2009. (Suppl; abstr LBA4511)
Woell E et al (2009). Oxaliplatin irinotecan and cetuximab in advanced gastric cancer First efficacy results of a multicenter phase II trial (AGMT Gastric-2). J Clin Oncol 27: 15s. (Suppl; abstr 4538)
Wöll E et al (2008). Biweekly Oxaliplatin and Irinotecan chemotherapy in advanced gastric cancer. A first line multicenter phase II trial of the arbeitsgemeinschaft medikamentöse tumortherapie (AGMT). Anticancer Res 28: 2901–2906
Kelsen D et al (2009). Analysis of survival with modified DCF and bevacizumab in patients with metastatic GE adenocarcinoma: results of a phase II clinical trial. J Clin Oncol 27: 15s. (Suppl; abstr 4512)
Thuss-Patience PC et al (2009). Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the arbeitsgemeinschaft internistische onkologie (AIO). J Clin Oncol 27: 15s. (Suppl; abstr 4540)
Jin M et al (2008). Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol 26: 15s. (Suppl; abstr 4533)
Ajani J et al (2009). Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. J Clin Oncol 27: 15s. (Suppl; abstr 4511)
Wöll E, DeVries A and Eisterer W et al (2008). Chemotherapy in gastric cancer. Anticancer Res 28: 1213–1220
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wöll, E. Gastric cancer – ASCO 2009. memo 2, 206–207 (2009). https://doi.org/10.1007/s12254-009-0161-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-009-0161-3